Paratek Pharmaceuticals Inc (PRTK)

NASDAQ
5.430
+0.090(+1.69%)
After Hours
5.910
+0.480(+8.84%)
- Real-time Data
  • Volume:
    855,235
  • Bid/Ask:
    5.920/5.990
  • Day's Range:
    5.320 - 5.490

PRTK Overview

Prev. Close
5.34
Day's Range
5.32-5.49
Revenue
55.44M
Open
5.34
52 wk Range
4.11-11.235
EPS
-1.92
Volume
855,235
Market Cap
254.82M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
549,713
P/E Ratio
-
Beta
1.52
1-Year Change
20.4%
Shares Outstanding
46,928,028
Next Earnings Date
Aug 09, 2021
What is your sentiment on Paratek Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Paratek Pharmaceuticals Inc News

Paratek Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyBuySellStrong Sell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong SellStrong Sell
SummaryNeutralStrong BuyStrong BuyStrong SellStrong Sell

Paratek Pharmaceuticals Inc Company Profile

Paratek Pharmaceuticals Inc Company Profile

Employees
197

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Read More
  • Worth a buy at $6.20?
    2
    • I think this one is going to go to 7.50 at least next week. let's see.
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.